GLP1R and type 2 diabetes mellitus: The FLOW trial is the first dedicated trial to assess the effect of a long-acting GLP1-RA for kidney or CV death protection among type 2 diabetes patients with varying degree of kidney impairment and albuminuria status (Novo Nordisk A/S, 2021).